Jiangsu Trautec Medical Technology (Trautec), founded in 2015, is dedicated with a mission of researching and developing synthetic recombinant human collagen (SRHC) biomaterials.
Trautec has over 17 million dollars invested in research and development (R&D) of synthetic recombinant human collagen (SRHC) production based on biomaterials. The 100,000 square feet production facility is based in Jiangsu, and its U.S. branch is headquartered in Ontario, California. The company will continue to expand the application of SRHC products in high-end fields such as medicine, medical regeneration and medical aesthetics, and occupy the forefront of the industry, aiming to build a global leading company in synthetic recombinant human collagen products.
